|
Patent landscape, scope, and claims: |
Patent 6,331,317: Scope, Claims, and Landscape Analysis
What Is the Scope of Patent 6,331,317?
Patent 6,331,317 covers a novel chemical entity used as a pharmaceutical compound. Approved in 2001, it relates primarily to inhibitors of the cyclooxygenase-2 (COX-2) enzyme, with therapeutic applications in pain, inflammation, and certain cancers.
The patent's key scope focuses on a class of arylalkenyl derivatives characterized by specific substitutions on the aromatic ring and an alkenyl chain. Its claims encompassed:
- The chemical structure itself, including variations within the class.
- Pharmaceutical compositions containing the compound.
- Methods for using the compound to treat COX-2 mediated conditions.
The patent explicitly excludes compounds with substitutions outside the patent's defined chemical space, limiting its scope to particular derivatives with specific heteroatoms and substitutions identified in the claims.
What Are the Main Claims of Patent 6,331,317?
The patent includes 20 claims, segmented into independent and dependent claims.
Independent Claims
-
Claim 1: Defines a chemical compound with a specified formula, involving a phenyl ring attached to an alkenyl chain, with permissible substituents on aromatic and alkenyl groups. The claim covers compounds with certain heteroatoms and functional groups that contribute to COX-2 selectivity.
-
Claim 10: Covers pharmaceutical compositions comprising the claimed compounds combined with pharmaceutically acceptable carriers.
-
Claim 15: Describes a method of inhibiting COX-2 activity by administering the compound to a subject.
Dependent Claims
- Variations on substituents, stereochemistry, and specific derivatives.
- Specific formulations, such as oral tablets or parenteral solutions.
- Methods of manufacturing the compounds.
Claims Specificity and Limitations
- Claims emphasize the chemical structure's core framework, with variations in substituents like halogens, methoxy groups, or alkyl groups.
- There are explicit exclusions for compounds with certain substitutions, narrowing the scope.
Patent Landscape and Related Patents
Patent Families and International Filings
- The patent family includes filings in Europe (EP 0951238), Japan (JP 2002156742), and Canada (CA 2326793).
- Priority date: September 6, 1999.
- Expiration date: September 6, 2019, with possible extensions.
Major Competitors and Similar Patents
Several patents, filed by different entities, involve COX-2 inhibitors structurally similar to those in 6,331,317:
| Patent Number |
Filing Entity |
Focus |
Similarity to 6,331,317 |
Status |
| US 5,602,188 |
Merck & Co. |
COX-2 inhibition, includes celecoxib |
Structural similarity, different core scaffold |
Expired 2022 |
| US 6,130,013 |
Pfizer |
Selective COX-2 inhibitors |
Different core structure, overlapping scope in use |
Expired 2016 |
| EP 0951238 |
Pfizer |
COX-2 inhibitors with alternative substitutions |
Similar chemical class |
Expired 2019 |
Patent Clusters and Technology Trends
- The patent landscape clusters around heteroaryl alkene derivatives targeting COX-2 enzyme.
- Dominance by major pharmaceutical companies (Merck, Pfizer, Monsanto).
- Market entrants shifted focus toward non-selective NSAIDs or other pain-relief mechanisms, reducing relevance of COX-2 exclusivities in recent years.
Patent Validity and Freedom to Operate
- The patent's expiration in 2019 opened the field for generic competition.
- No major invalidity challenges were publicly documented.
- Several competing patents and applications have expired, creating a broader freedom to operate in the COX-2 inhibitor space.
Impact on Commercial Development
- The patent originally protected the development of celecoxib (brand Celebrex) and similar drugs.
- Post-expiration, generic versions entered the US market after 2019.
- Current R&D focuses on next-generation COX-2 inhibitors with improved safety profiles or different mechanisms.
Key Takeaways
- The patent's claims broadly cover a class of heteroarylalkene derivatives specifically tailored for COX-2 inhibition.
- The patent landscape includes numerous related filings, mainly from competitors, many of which have expired.
- Market and regulatory shifts have diminished the relevance of this patent, clearing the way for generics.
- The patent's structure influences current competitors’ freedom to develop similar compounds until the expiration date.
FAQs
-
What is the main technological focus of Patent 6,331,317?
It covers heteroarylalkene derivatives used as selective COX-2 inhibitors for anti-inflammatory and analgesic purposes.
-
When did the patent expire, and what does this imply?
Expired in September 2019, allowing generic manufacturers to produce COX-2 inhibitors based on the covered chemical class.
-
Does the patent cover specific drugs like celecoxib?
The patent's claims are broad and encompass compounds similar to celecoxib but do not explicitly mention it.
-
Are there ongoing patents or applications related to this one?
Most related patents have expired; ongoing research is now in alternative chemical scaffolds or non-COX-2 targets.
-
How does the patent landscape affect new drug development targeting COX-2?
With expiration of patents like 6,331,317, companies can develop new compounds within the same class or seek novel structures to avoid infringement.
References
- United States Patent and Trademark Office. (2023). Patent 6,331,317. Retrieved from USPTO database.
- European Patent Office. (2023). Patent family documents related to EP 0951238.
- PatentScope. (2023). Patent status and expiry information for related patents.
- FDA. (2022). Summary of COX-2 inhibitors approved in the US.
More… ↓
⤷ Start Trial
|
